Chemours Analyst Ratings
Chemours Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/30/2023 | 18.74% | Barclays | $31 → $28 | Maintains | Equal-Weight |
10/04/2023 | 31.47% | Barclays | $40 → $31 | Maintains | Equal-Weight |
08/02/2023 | 124.77% | BMO Capital | $64 → $53 | Maintains | Outperform |
08/01/2023 | 39.95% | Morgan Stanley | $33 → $33 | Reiterates | Equal-Weight → Equal-Weight |
07/31/2023 | 69.64% | RBC Capital | $37 → $40 | Maintains | Sector Perform |
07/19/2023 | 39.95% | Morgan Stanley | $33 → $33 | Reiterates | Equal-Weight → Equal-Weight |
07/11/2023 | 69.64% | Barclays | $38 → $40 | Maintains | Equal-Weight |
06/22/2023 | 56.91% | B of A Securities | $41 → $37 | Downgrades | Buy → Neutral |
06/13/2023 | 82.36% | UBS | $41 → $43 | Maintains | Buy |
06/09/2023 | 56.91% | RBC Capital | $36 → $37 | Maintains | Sector Perform |
06/05/2023 | 171.42% | BMO Capital | $54 → $64 | Maintains | Outperform |
05/31/2023 | 27.23% | JP Morgan | $35 → $30 | Maintains | Neutral |
05/01/2023 | 52.67% | RBC Capital | $35 → $36 | Maintains | Sector Perform |
05/01/2023 | 129.01% | BMO Capital | $52 → $54 | Maintains | Outperform |
04/28/2023 | 6.02% | Credit Suisse | $27 → $25 | Maintains | Underperform |
02/14/2023 | 61.15% | Goldman Sachs | $34 → $38 | Maintains | Neutral |
02/13/2023 | 48.43% | Citigroup | $33 → $35 | Maintains | Neutral |
02/13/2023 | 52.67% | RBC Capital | $33 → $36 | Maintains | Sector Perform |
02/10/2023 | 14.5% | Credit Suisse | $24 → $27 | Maintains | Underperform |
01/24/2023 | 82.36% | UBS | $31 → $43 | Upgrades | Neutral → Buy |
01/11/2023 | 31.47% | UBS | $29 → $31 | Maintains | Neutral |
01/11/2023 | 69.64% | B of A Securities | $37 → $40 | Upgrades | Neutral → Buy |
01/10/2023 | 39.95% | RBC Capital | $35 → $33 | Downgrades | Outperform → Sector Perform |
12/15/2022 | 39.95% | Citigroup | $30 → $33 | Maintains | Neutral |
11/01/2022 | 1.78% | Credit Suisse | → $24 | Initiates Coverage On | → Underperform |
10/27/2022 | 73.88% | BMO Capital | $46 → $41 | Maintains | Outperform |
10/25/2022 | 39.95% | Morgan Stanley | $41 → $33 | Maintains | Equal-Weight |
10/13/2022 | 27.23% | Goldman Sachs | → $30 | Initiates Coverage On | → Neutral |
10/05/2022 | — | Argus Research | Downgrades | Buy → Hold | |
09/27/2022 | 27.23% | Barclays | $46 → $30 | Maintains | Equal-Weight |
09/23/2022 | 95.08% | BMO Capital | $55 → $46 | Maintains | Outperform |
09/22/2022 | 48.43% | RBC Capital | $48 → $35 | Maintains | Outperform |
08/01/2022 | 103.56% | RBC Capital | $44 → $48 | Maintains | Outperform |
07/29/2022 | 56.91% | UBS | $35 → $37 | Maintains | Neutral |
06/14/2022 | 86.6% | B of A Securities | $48 → $44 | Downgrades | Buy → Neutral |
05/09/2022 | 73.88% | Morgan Stanley | $35 → $41 | Maintains | Equal-Weight |
05/09/2022 | 95.08% | Barclays | $37 → $46 | Maintains | Equal-Weight |
05/04/2022 | 103.56% | RBC Capital | $42 → $48 | Maintains | Outperform |
02/15/2022 | 73.88% | RBC Capital | $44 → $41 | Maintains | Outperform |
02/14/2022 | 27.23% | JP Morgan | $35 → $30 | Maintains | Neutral |
01/04/2022 | 52.67% | UBS | $34 → $36 | Maintains | Neutral |
11/08/2021 | 90.84% | RBC Capital | $40 → $45 | Maintains | Outperform |
08/03/2021 | 69.64% | RBC Capital | $35 → $40 | Maintains | Outperform |
06/10/2021 | — | Wolfe Research | Initiates Coverage On | → Outperform | |
06/09/2021 | 99.32% | Goldman Sachs | $35 → $47 | Upgrades | Neutral → Buy |
05/20/2021 | 78.12% | B of A Securities | → $42 | Initiates Coverage On | → Buy |
05/10/2021 | 48.43% | Morgan Stanley | $30 → $35 | Maintains | Equal-Weight |
05/06/2021 | 69.64% | Argus Research | → $40 | Upgrades | Hold → Buy |
02/16/2021 | 27.23% | Morgan Stanley | $28 → $30 | Maintains | Equal-Weight |
01/08/2021 | 48.43% | RBC Capital | $27 → $35 | Upgrades | Sector Perform → Outperform |
12/14/2020 | 18.74% | Morgan Stanley | $23 → $28 | Maintains | Equal-Weight |
12/04/2020 | 18.74% | Barclays | $26 → $28 | Downgrades | Overweight → Equal-Weight |
11/16/2020 | -2.46% | Morgan Stanley | $12 → $23 | Maintains | Equal-Weight |
11/05/2020 | 18.74% | BMO Capital | $26 → $28 | Maintains | Outperform |
08/04/2020 | -23.66% | Citigroup | $16 → $18 | Maintains | Neutral |
08/03/2020 | -19.42% | RBC Capital | $15 → $19 | Maintains | Sector Perform |
07/09/2020 | -36.39% | UBS | $12 → $15 | Maintains | Neutral |
05/08/2020 | -49.11% | UBS | $9 → $12 | Maintains | Neutral |
05/07/2020 | -49.11% | SunTrust Robinson Humphrey | $10 → $12 | Maintains | Hold |
04/09/2020 | -66.07% | Citigroup | $10 → $8 | Maintains | Neutral |
04/03/2020 | -53.35% | CFRA | $21 → $11 | Downgrades | Strong Buy → Hold |
04/01/2020 | -53.35% | RBC Capital | $13 → $11 | Maintains | Sector Perform |
03/30/2020 | -49.11% | Morgan Stanley | $15 → $12 | Maintains | Equal-Weight |
03/26/2020 | -10.94% | BMO Capital | $33 → $21 | Maintains | Outperform |
02/18/2020 | -19.42% | SunTrust Robinson Humphrey | $17 → $19 | Maintains | Hold |
12/20/2019 | -19.42% | JP Morgan | $21 → $19 | Maintains | Neutral |
11/07/2019 | 6.02% | BMO Capital | $23 → $25 | Maintains | Outperform |
11/06/2019 | -10.94% | Citigroup | $14 → $21 | Maintains | Neutral |
10/02/2019 | -38.51% | UBS | $19 → $14.5 | Maintains | Neutral |
09/09/2019 | -2.46% | BMO Capital | $31 → $23 | Maintains | Outperform |
08/20/2019 | -23.66% | Susquehanna | $37 → $18 | Upgrades | Neutral → Positive |
08/09/2019 | — | RBC Capital | Downgrades | Outperform → Sector Perform | |
08/06/2019 | — | Argus Research | Downgrades | Buy → Hold | |
08/05/2019 | 31.47% | BMO Capital | $45 → $31 | Maintains | Outperform |
05/06/2019 | — | JP Morgan | Downgrades | Overweight → Neutral | |
04/15/2019 | 120.53% | SunTrust Robinson Humphrey | → $52 | Upgrades | Hold → Buy |
02/19/2019 | — | Susquehanna | Downgrades | Positive → Neutral | |
11/05/2018 | 145.97% | BMO Capital | $68 → $58 | Maintains | Outperform |
11/02/2018 | 61.15% | Citigroup | $44 → $38 | Downgrades | Buy → Neutral |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
2023年10月30日 | 18.74% | 巴克莱 | $31→$28 | 维护 | 等重 |
10/04/2023 | 31.47% | 巴克莱 | $40→$31 | 维护 | 等重 |
08/02/2023 | 124.77% | 蒙特利尔银行资本 | $64→$53 | 维护 | 跑赢大盘 |
08/01/2023 | 39.95% | 摩根士丹利 | $33→$33 | 重申 | 等重→等重 |
07/31/2023 | 69.64% | 加拿大皇家银行资本 | $37→$40 | 维护 | 行业表现 |
07/19/2023 | 39.95% | 摩根士丹利 | $33→$33 | 重申 | 等重→等重 |
07/11/2023 | 69.64% | 巴克莱 | $38→$40 | 维护 | 等重 |
2023/06/22 | 56.91% | B of A证券 | $41→$37 | 评级下调 | 购买→中性 |
2023/06/13 | 82.36% | 瑞银集团 | $41→$43 | 维护 | 买 |
06/09/2023 | 56.91% | 加拿大皇家银行资本 | $36→$37 | 维护 | 行业表现 |
06/05/2023 | 171.42% | 蒙特利尔银行资本 | $54→$64 | 维护 | 跑赢大盘 |
2023年05月31日 | 27.23% | 摩根大通 | $35→$30 | 维护 | 中性 |
05/01/2023 | 52.67% | 加拿大皇家银行资本 | $35→$36 | 维护 | 行业表现 |
05/01/2023 | 129.01% | 蒙特利尔银行资本 | $52→$54 | 维护 | 跑赢大盘 |
04/28/2023 | 6.02% | 瑞士信贷 | $27→$25 | 维护 | 表现不佳 |
02/14/2023 | 61.15% | 高盛 | $34→$38 | 维护 | 中性 |
02/13/2023 | 48.43% | 花旗集团 | $33→$35 | 维护 | 中性 |
02/13/2023 | 52.67% | 加拿大皇家银行资本 | $33→$36 | 维护 | 行业表现 |
02/10/2023 | 14.5% | 瑞士信贷 | $24→$27 | 维护 | 表现不佳 |
01/24/2023 | 82.36% | 瑞银集团 | $31→$43 | 升级 | 中性→购买 |
2023年1月11日 | 31.47% | 瑞银集团 | $29→$31 | 维护 | 中性 |
2023年1月11日 | 69.64% | B of A证券 | $37→$40 | 升级 | 中性→购买 |
2023年1月10日 | 39.95% | 加拿大皇家银行资本 | $35→$33 | 评级下调 | 跑赢→板块表现 |
2022年12月15日 | 39.95% | 花旗集团 | $30→$33 | 维护 | 中性 |
11/01/2022 | 1.78% | 瑞士信贷 | →$24 | 开始承保 | →表现不佳 |
10/27/2022 | 73.88% | 蒙特利尔银行资本 | $46→$41 | 维护 | 跑赢大盘 |
2022年10月25日 | 39.95% | 摩根士丹利 | $41→$33 | 维护 | 等重 |
10/13/2022 | 27.23% | 高盛 | →$30 | 开始承保 | →中性 |
10/05/2022 | - | Argus研究 | 评级下调 | 购买→Hold | |
09/27/2022 | 27.23% | 巴克莱 | $46→$30 | 维护 | 等重 |
09/23/2022 | 95.08% | 蒙特利尔银行资本 | $55→$46 | 维护 | 跑赢大盘 |
09/22/2022 | 48.43% | 加拿大皇家银行资本 | $48→$35 | 维护 | 跑赢大盘 |
08/01/2022 | 103.56% | 加拿大皇家银行资本 | $44→$48 | 维护 | 跑赢大盘 |
07/29/2022 | 56.91% | 瑞银集团 | $35→$37 | 维护 | 中性 |
2022/06/14 | 86.6% | B of A证券 | $48→$44 | 评级下调 | 购买→中性 |
05/09/2022 | 73.88% | 摩根士丹利 | $35→$41 | 维护 | 等重 |
05/09/2022 | 95.08% | 巴克莱 | $37→$46 | 维护 | 等重 |
05/04/2022 | 103.56% | 加拿大皇家银行资本 | $42→$48 | 维护 | 跑赢大盘 |
02/15/2022 | 73.88% | 加拿大皇家银行资本 | $44→$41 | 维护 | 跑赢大盘 |
02/14/2022 | 27.23% | 摩根大通 | $35→$30 | 维护 | 中性 |
01/04/2022 | 52.67% | 瑞银集团 | $34→$36 | 维护 | 中性 |
11/08/2021 | 90.84% | 加拿大皇家银行资本 | $40→$45 | 维护 | 跑赢大盘 |
08/03/2021 | 69.64% | 加拿大皇家银行资本 | $35→$40 | 维护 | 跑赢大盘 |
2021/10/06 | - | 沃尔夫研究 | 开始承保 | →跑赢大盘 | |
06/09/2021 | 99.32% | 高盛 | $35→$47 | 升级 | 中性→购买 |
05/20/2021 | 78.12% | B of A证券 | →$42 | 开始承保 | →购买 |
2021/05/10 | 48.43% | 摩根士丹利 | $30→$35 | 维护 | 等重 |
05/06/2021 | 69.64% | Argus研究 | →$40 | 升级 | 持有→购买 |
02/16/2021 | 27.23% | 摩根士丹利 | $28→$30 | 维护 | 等重 |
01/08/2021 | 48.43% | 加拿大皇家银行资本 | $27→$35 | 升级 | 行业表现优于→ |
12/14/2020 | 18.74% | 摩根士丹利 | $23→$28 | 维护 | 等重 |
12/04/2020 | 18.74% | 巴克莱 | $26→$28 | 评级下调 | 超重→等重 |
11/16/2020 | -2.46% | 摩根士丹利 | $12→$23 | 维护 | 等重 |
11/05/2020 | 18.74% | 蒙特利尔银行资本 | $26→$28 | 维护 | 跑赢大盘 |
08/04/2020 | -23.66% | 花旗集团 | $16→$18 | 维护 | 中性 |
08/03/2020 | -19.42% | 加拿大皇家银行资本 | $15→$19 | 维护 | 行业表现 |
07/09/2020 | -36.39% | 瑞银集团 | $12→$15 | 维护 | 中性 |
05/08/2020 | -49.11% | 瑞银集团 | $9→$12 | 维护 | 中性 |
05/07/2020 | -49.11% | SunTrust Robinson Humphrey | $10→$12 | 维护 | 保持 |
04/09/2020 | -66.07% | 花旗集团 | $10→$8 | 维护 | 中性 |
04/03/2020 | -53.35% | CFRA | $21→$11 | 评级下调 | 强力买入→Hold |
04/01/2020 | -53.35% | 加拿大皇家银行资本 | $13→$11 | 维护 | 行业表现 |
03/30/2020 | -49.11% | 摩根士丹利 | $15→$12 | 维护 | 等重 |
03/26/2020 | -10.94% | 蒙特利尔银行资本 | $33→$21 | 维护 | 跑赢大盘 |
02/18/2020 | -19.42% | SunTrust Robinson Humphrey | $17→$19 | 维护 | 保持 |
2019年12月20日 | -19.42% | 摩根大通 | $21→$19 | 维护 | 中性 |
2019/07/11 | 6.02% | 蒙特利尔银行资本 | $23→$25 | 维护 | 跑赢大盘 |
2019/06/11 | -10.94% | 花旗集团 | $14→$21 | 维护 | 中性 |
2019年10月02日 | -38.51% | 瑞银集团 | $19→$14.5 | 维护 | 中性 |
2019年09月09日 | -2.46% | 蒙特利尔银行资本 | $31→$23 | 维护 | 跑赢大盘 |
2019年08月20日 | -23.66% | 萨斯奎哈纳 | $37→$18 | 升级 | 中性→阳性 |
2019年08月09日 | - | 加拿大皇家银行资本 | 评级下调 | 跑赢→板块表现 | |
2019年08月06日 | - | Argus研究 | 评级下调 | 购买→Hold | |
2019年08月05日 | 31.47% | 蒙特利尔银行资本 | $45→$31 | 维护 | 跑赢大盘 |
2019年05月06日 | - | 摩根大通 | 评级下调 | 超重→中性 | |
2019年04月15日 | 120.53% | SunTrust Robinson Humphrey | →$52 | 升级 | 持有→购买 |
2019年02月19日 | - | 萨斯奎哈纳 | 评级下调 | 正→中性 | |
2018年11月05日 | 145.97% | 蒙特利尔银行资本 | $68→$58 | 维护 | 跑赢大盘 |
11/02/2018 | 61.15% | 花旗集团 | $44→$38 | 评级下调 | 购买→中性 |
What is the target price for Chemours (CC)?
化学(CC)的目标价格是多少?
The latest price target for Chemours (NYSE: CC) was reported by Barclays on October 30, 2023. The analyst firm set a price target for $28.00 expecting CC to rise to within 12 months (a possible 18.74% upside). 25 analyst firms have reported ratings in the last year.
巴克莱银行于2023年10月30日报告了科慕(NYSE:CC)的最新目标价。该分析公司将价格目标定为28.00美元,预计CC将在12个月内上涨(可能上涨18.74%)。去年有25家分析公司公布了评级。
What is the most recent analyst rating for Chemours (CC)?
化学(CC)的最新分析师评级是多少?
The latest analyst rating for Chemours (NYSE: CC) was provided by Barclays, and Chemours maintained their equal-weight rating.
最新的分析师对化学(纽约证券交易所代码:CC)的评级是由巴克莱提供的,化学维持其同等权重的评级。
When is the next analyst rating going to be posted or updated for Chemours (CC)?
化学(CC)的下一次分析师评级将于何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemours, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemours was filed on October 30, 2023 so you should expect the next rating to be made available sometime around October 30, 2024.
分析师在做了广泛的研究后得出了股票评级,研究内容包括查阅公开财务报表、与科慕的高管和客户交谈,以及收听收益电话会议。大多数分析师每三个月做一次,所以你每年应该对每家公司进行4次评级。Chemours的最后一次评级于2023年10月30日提交,因此您应该期待下一次评级将于2024年10月30日左右提供。
Is the Analyst Rating Chemours (CC) correct?
分析师对化学(CC)的评级正确吗?
While ratings are subjective and will change, the latest Chemours (CC) rating was a maintained with a price target of $31.00 to $28.00. The current price Chemours (CC) is trading at is $23.58, which is out of the analyst's predicted range.
虽然评级是主观的,会发生变化,但最新的科慕(CC)评级是维持在31.00美元至28.00美元的目标价格。Chemours(CC)目前的交易价格为23.58美元,超出了分析师的预测范围。